文献速递免疫规划妇幼与学校卫生

马里母婴脑膜炎球菌IgG抗体动力学研究

Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants.
PubMed 文献 · Vaccine · 2019-04-02

在马里开展的前瞻性随机对照观察者盲试验中,孕期接种四价脑膜炎球菌结合疫苗(MCV)的50对母婴亚组显示, infant出生时MenA特异性IgG≥2µg/mL比例为94.0%,3月龄降至72.9%,6月龄降至30.4%;MenC、MenY、MenW出生时分别为81.3%、89.6%、89.6%,3月龄和6月龄均下降。母体接种MCV在多数婴儿中可提供出生至3月龄的保护性IgG水平。

要点

  • 母体接种MCV后,多数婴儿出生时四种血清群IgG≥2µg/mL。
  • 抗体水平随月龄下降,6月龄时各血清群保护比例明显降低。
  • 母体免疫可桥接出生至3月龄的保护窗口。

核心结论

  • 孕期接种四价脑膜炎球菌结合疫苗在多数婴儿中可传递出生至3月龄的保护性IgG水平。

研究设计与样本

  • 在马里开展的前瞻性、随机、对照、观察者盲试验,比较三价流感疫苗与四价脑膜炎球菌结合疫苗(MCV)的免疫原性。
  • 选取50对母亲接种MCV的母婴配对,采集母亲接种前、接种后28天、分娩时及产后3、6个月血样,以及婴儿出生、3、6月龄血样。
  • 采用酶联免疫吸附试验检测A、C、Y、W血清群特异性抗体。

主要发现

  • 出生时94.0%(47/50)婴儿MenA特异性IgG≥2µg/mL,3月龄降至72.9%,6月龄降至30.4%。
  • 出生时81.3%(39/48)婴儿MenC特异性IgG≥2µg/mL,3月龄降至29.4%,6月龄降至17.8%。
  • 出生时89.6%(43/48)婴儿MenY特异性IgG≥2µg/mL,3月龄降至64.6%,6月龄降至62.5%。
  • 出生时89.6%(43/48)婴儿MenW特异性IgG≥2µg/mL,3月龄降至62.5%,6月龄降至41.7%。

临床怎么用

  • 提示母体MCV接种可保护婴儿出生至3月龄,支持孕期免疫作为脑膜炎球菌病早期防护策略。
  • 6月龄时多数血清群保护性抗体比例明显下降,需关注后续婴儿免疫规划衔接。

局限性

  • 仅分析50对母婴随机子集,样本量有限。
  • 原文未报告保护性阈值以外的临床结局或长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A prospective, randomised, controlled observer-blind trial measuring the efficacy and immunogenicity of trivalent influenza vaccine (TIV) and the immunogenicity of quadrivalent meningococcal conjugate vaccine (MCV) in pregnant women and their infants up to 6 months of age was conducted in Mali. Here we reported the immunogenicity of MCV, which was used as a comparator vaccine to TIV, in this population. Third-trimester pregnant Malian women were randomized to receive TIV or MCV. Blood samples were collected from women prior to vaccination, 28 days post-vaccination, at delivery and 3 and 6 months post-delivery and from infants at birth and 3 and 6 months of age. Meningococcal-specific serogroup (Men) A, C, Y and W-specific antibodies were measured by enzyme linked immunosorbent assay in a randomly selected subset of 50 mother-infant pairs where the mother had received MCV. At birth, 94.0% (47/50) of infants had MenA specific IgG levels ≥ 2 µg/mL decreasing to 72.9% and 30.4% at 3 and 6 months of age. For MenC, 81.3% (39/48) of infants had MenC specific IgG levels ≥ 2 µg/mL at birth decreasing to 29.4% and 17.8% at 3 and 6 months of age. For MenY, 89.6% (43/48) of infants had MenY specific IgG levels ≥ 2 µg/mL at birth decreasing to 64.6% and 62.5% at 3 and 6 months of age. For MenW, 89.6% (43/48) of infants had MenW specific IgG levels ≥ 2 μg/ml at birth decreasing to 62.5% and 41.7% at 3 and 6 months of age. Maternal immunization with MCV conveyed protective levels of IgG at birth through to 3 months of age in the majority of infants.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Findlow H, Tapia MD, Sow SO, et al. Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants. Vaccine. 2019. PMID: 30952500. doi:10.1016/j.vaccine.2019.03.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。